Skip to content
drillr.ai

CAPR

Capricor Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$19.50+0.31%

Price as of Jul 20, 2026

CAPR news

Capricor Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

    –Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on track with PDUFA target action date of August 22, 2026– SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (https://www.globenewswire.com/Tracker?data=AZcayUcDGZHovCSDoZdE7qPvZOqELzOSExPNopIqX1qKQQKSEWJRQ4LLvXP6FsP1omF3c_iOv4TkY_Iif9If9xqEfRhfp7sL19uZ2dNdLmdJAow914iFJTObmSM2ROKqXwgSbkmsZptlnShlYy8KWryZWI7hUzHPR4g5hj_x1vTdQLCyyczizUgf09B5kLmANdi8dutE9USComoAVelaQlLdJ304Gznwpab0wDk

    Globe Newswire ·

  2. Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

    * Deramiocel demonstrates durable skeletal and cardiac muscle benefit over five years in the HOPE-2 OLE study * PUL 2.0 year-over-year decline attenuated to approximately 1 point * Findings to be presented alongside previously reported HOPE-3 Phase 3 results, which met its primary and key secondary endpoints with statistical significance * Deramiocel maintains a favorable safety profile across both studies, with no new safety signals * HOPE-2 OLE data featured in a late-breaking session; HOPE-3

    Globe Newswire ·

  3. Capricor Therapeutics to Present at Upcoming Investor Conferences

    SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (https://www.globenewswire.com/Tracker?data=45EzjD_MRxDC7t6_7E1adJDGYCNn-3TyfwICpaY4yQdl9JLyon9mldNy7zvZDSu3vsUZDMIDFQW_OQqH-ujQkjC3p-nwxfHYI8gg_kd8b9xPfFxXjeZXeRjafqd1zJdnFmoM4MlvyJuo7ceeh_1k86nbNWwMojVAY2C4--XDziL9NnazkZgzGjnbX1AHs4I43-f_32h79ia9xwf5jhRQqBXmDMfPRwVggGgIdY0qXukRBoH3FO7Hqbr44uee-GVT5gmjyc4tX-vunrUpDUSq-CT5SesetsWyldEgBmeA-3dQOPyuzSTAn-iJ1aCHK-NPOOP8KkyOH5hXqpEquhMNS6U0sdfKx7YPFqYchcWnLhDJzJztZ6bxhXO-BnDii5oOLbyeW

    Globe Newswire ·

  4. Caprock Announces Plans to Commence Drill Program Designed for Pit-Constrained Mineral Resource Expansion at Destiny

    Toronto, Ontario--(Newsfile Corp. - April 22, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock", or the "Company") is pleased to announce plans to commence a shallow drill program designed to expand the current open pit-constrained Mineral Resource Estimate ("MRE", or "Mineral Resource") westward at its flagship Destiny gold property ("Destiny", or the "Property", or the "Project"), located near Val d'Or, Quebec. Caprock's President & CEO, Mr. Vishal Gupta, stated, "Our recently concluded dee

    Newsfile Corp ·

  5. Caprock Intersects 38.48 g/t Au over 1.6m Included Within a Broader Interval of 2.84 g/t over 23.2m at Destiny

    Toronto, Ontario--(Newsfile Corp. - March 25, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock", or the "Company") is pleased to announce high-grade assay results for drill hole DES-26-183 from the ongoing drill program at its flagship Destiny gold property ("Destiny", or the "Property", or the "Project"), located near Val d'Or, Quebec. Key Assay Highlights from Drill Hole DES-26-183: * 38.48 g/t Au over 1.6m, included within 2.84 g/t Au over 23.2m ; * 6.24 g/t Au over 1.0m and 2.78 g/t Au ove

    Newsfile Corp ·

  6. Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.

    Toronto, Ontario--(Newsfile Corp. - March 23, 2026) - Frank Guillemette (the "Acquiror ") announces that, on March 18, 2026, he acquired an aggregate of 957,000 common shares in the capital of Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Issuer") through the facilities of the Canadian Securities Exchange for total consideration of $105,476.97 CAD (the "Acquisition"). Immediately prior to the Acquisition, the Acquiror held 11,043,366 common shares and 4,633,333 common share purchase warran

    Newsfile Corp ·

  7. Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    * Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026 * Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF) * Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefits * San Diego GMP manufacturing facility operational to support potential commercial launch * Capricor uplisted to the Nasdaq Global Select Market * Cash balance of a

    Globe Newswire ·

  8. Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)

    SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether certain officers and directors of Atkore Inc. (NYSE: ATKR), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Capricor Therapeutics, Inc. (NASDAQ: CAPR), and CTO Realty Growth, Inc. (NYSE: CTO) breached the fiduciary duties they owed to the Company. Shareholders who have held shares continuously since prior to the dates listed below may have standing to seek corporate governance reforms, the return of funds to th

    Globe Newswire ·

  9. Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

    * Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophy * BLA supported by positive pivotal HOPE-3 Phase 3 results, including achievement of the primary endpoint and all Type I error-controlled secondary endpoints * PDUFA target action date set for August 22, 2026; Company expects to be eligible for a Priority Review Voucher upon potential approval SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeu

    Globe Newswire ·